Amgen announces ‘positive’ Phase II lung cancer results for cancer drug with hard-to-reach target Posted on October 6, 2020 by Nile The company did not provide data, but said results for patients who received sotorasib at the 960mg dose were consistent with those seen in the Phase I portion of the Phase I/II study, which showed an overall response rate of 35.3%. ……